Delcath Systems Inc.

2.75-0.0500-1.79%Vol 379.43K1Y Perf -1.75%
Nov 30th, 2023 16:00 DELAYED
BID2.72 ASK2.79
Open2.80 Previous Close2.80
Pre-Market- After-Market-
 - -  - -%
Target Price
17.25 
Analyst Rating
Strong Buy 1.00
Potential %
527.27 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
     25.07
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
     35.28
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.71 
Earnings Rating
Market Cap60.63M 
Earnings Date
13th Nov 2023
Alpha-0.04 Standard Deviation0.21
Beta0.70 

Today's Price Range

2.692.91

52W Range

2.257.99

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-8.03%
1 Month
-11.58%
3 Months
-43.42%
6 Months
-63.38%
1 Year
-1.75%
3 Years
-82.65%
5 Years
-98.84%
10 Years
-100.00%

TickerPriceChg.Chg.%
DCTH2.75-0.0500-1.79
AAPL189.910.54000.29
GOOG133.91-2.4900-1.83
MSFT378.73-0.1200-0.03
XOM102.740.40000.39
WFC44.590.81001.85
JNJ154.662.55001.68
FB196.640.99000.51
GE121.802.94002.47
JPM156.081.76001.14
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.30
0.72
3.13
-10.60
Leverage Ratio -19.50
ProfitabilityValueIndustryS&P 500US Markets
73.10
-692.10
-689.10
-901.80
-
RevenueValueIndustryS&P 500US Markets
2.08M
0.21
11.93
0.95
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.67-0.5813.43
Q01 2023-0.57-0.77-35.09
Q04 2022-0.68-0.86-26.47
Q03 2022-1.05-0.9212.38
Q02 2022-0.88-1.18-34.09
Q01 2022-0.84-1.00-19.05
Q04 2021-0.93-0.6925.81
Q03 2021-0.91-0.94-3.30
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.50
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume379.43K
Shares Outstanding22.05K
Shares Float19.70M
Trades Count1.59K
Dollar Volume1.05M
Avg. Volume311.18K
Avg. Weekly Volume177.38K
Avg. Monthly Volume413.01K
Avg. Quarterly Volume343.14K

Delcath Systems Inc. (NASDAQ: DCTH) stock closed at 2.75 per share at the end of the most recent trading day (a -1.79% change compared to the prior day closing price) with a volume of 379.43K shares and market capitalization of 60.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 36 people. Delcath Systems Inc. CEO is Gerard J. Michel.

The one-year performance of Delcath Systems Inc. stock is -1.75%, while year-to-date (YTD) performance is -23.61%. DCTH stock has a five-year performance of -98.84%. Its 52-week range is between 2.25 and 7.99, which gives DCTH stock a 52-week price range ratio of 8.71%

Delcath Systems Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 7.01, a price-to-sale (PS) ratio of 17.24, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -128.42%, a ROC of -148.47% and a ROE of -1 353.03%. The company’s profit margin is -%, its EBITDA margin is -689.10%, and its revenue ttm is $2.08 Million , which makes it $0.21 revenue per share.

Of the last four earnings reports from Delcath Systems Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Delcath Systems Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Delcath Systems Inc. is Strong Buy (1), with a target price of $17.25, which is +527.27% compared to the current price. The earnings rating for Delcath Systems Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Delcath Systems Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Delcath Systems Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.95, ATR14 : 0.23, CCI20 : -47.95, Chaikin Money Flow : -0.13, MACD : -0.18, Money Flow Index : 68.41, ROC : -6.78, RSI : 39.78, STOCH (14,3) : 53.57, STOCH RSI : 0.00, UO : 37.15, Williams %R : -46.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Delcath Systems Inc. in the last 12-months were: Advisors, Inc. Rosalind (Buy at a value of $240 000), David L. Hoffman (Buy at a value of $99 200), Gerard J. Michel (Buy at a value of $251 061), John Purpura (Buy at a value of $49 897), Michel Gerard (Buy at a value of $101 298), Pennell Sandra (Buy at a value of $72 900), Steven Salamon (Buy at a value of $55 045), Sylvester John (Buy at a value of $50 640), Vojo Vukovic (Buy at a value of $148 800)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

CEO: Gerard J. Michel

Telephone: +1 212 489-2100

Address: 1633 Broadway, New York 10019, NY, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

 

TipRanks News for DCTH

Tue, 15 Aug 2023 13:40 GMT Unusually active option classes on open August 15th

- TipRanks. All rights reserved.

News

Stocktwits